Proteins and Peptides

06 Mar 2018 Lyric Completes Enrollment in Phase 2 PROMOTE Study of LP101 (Ulimorelin) in Enteral Feeding Intolerance
06 Mar 2018 Symic Bio Announces Results of Locally-Administered Therapeutic SB-030 in Preclinical Model of Vascular Intervention
06 Mar 2018 Shire launches MyPKFit for Advate® [antihemophilic factor (recombinant)] in the U.S.
06 Mar 2018 Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase
03 Mar 2018 STADA: EMA started the evaluation of resubmitted marketing authorisation application for biosimilar pegfilgrastim
02 Mar 2018 European Authorities Approve JHL Biotech's Clinical Trial Application for Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis
28 Feb 2018 U.S. FDA Accepts Shire's Biologics License Application for Calaspargase Pegol (Cal-PEG) for Acute Lymphoblastic Leukemia (ALL)
27 Feb 2018 Novo Nordisk files for regulatory approval of long-acting factor VIII (N8-GP) in the US and the EU for treatment of haemophilia A
25 Feb 2018 Kineret® (anakinra) Receives a Positive Opinion from CHMP for the Treatment of Still's Disease
22 Feb 2018 Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage
22 Feb 2018 Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide
22 Feb 2018 DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke
21 Feb 2018 Orano Med and RadioMedix announce dosing of first patients in AlphaMedix™ Phase 1 clinical trial
19 Feb 2018 sterna biologicals Reports Phase 2a Study Data Demonstrating Efficacy of Its GATA-3 Specific DNAzyme Formulation SB012 in Patients with Ulcerative Colitis
18 Feb 2018 Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™
16 Feb 2018 Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia
15 Feb 2018 IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3
14 Feb 2018 Therachon Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia
14 Feb 2018 Herantis Pharma opening recruitment in Parkinson's disease study in Helsinki and Lund based on favorable first CDNF safety assessment
13 Feb 2018 Bicycle Therapeutics and Cancer Research UK Announce Initiation of First Clinical Study of a Bicyclic Peptide (Bicycle®)
13 Feb 2018 Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
13 Feb 2018 Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria
09 Feb 2018 Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB 2679d/ISU304 in Individuals with Hemophilia B
09 Feb 2018 Novo Nordisk A/S: Ozempic® (semaglutide) approved in the EU for the treatment of type 2 diabetes
08 Feb 2018 Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up